Exelixis Inc. (EXEL) 7.34 $EXEL
Exelixis Shares Up 45.1% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Wed Jun 08, 12:57PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 45.12% as of today's recent price of $7.14.
EXEL: 7.34 (-0.03)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 38.87 (-0.04), JNJ: 116.15 (-0.85), PFE: 35.10 (-0.21), EXEL: 7.34 (-0.03)
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 53.69 (-2.11), EXEL: 7.34 (-0.03)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 35.10 (-0.21), BMY: 72.18 (-0.55), EXEL: 7.34 (-0.03)
SmarTrend Watching for Potential Pullback in Shares of Exelixis After 8.35% Gain
Comtex SmarTrend(R) - Mon Jun 06, 2:44PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.76 to a high of $7.34. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.80 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 7.34 (-0.03)
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX(TM) (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
BusinessWire - Sun Jun 05, 6:53AM CDT
--- Overall survival and progression-free survival benefits consistent across all subgroups evaluated -
EXEL: 7.34 (-0.03)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 7.34 (-0.03)
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
BusinessWire - Sun Jun 05, 6:30AM CDT
--- Phase 3 pivotal trial of combination has been initiated -
EXEL: 7.34 (-0.03)
Exelixis Rises 4.27% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 3:16PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.46 to a high of $6.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $6.63 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Uptrend Call Working As Exelixis Stock Rises 31.9% (EXEL)
Comtex SmarTrend(R) - Wed Jun 01, 12:52AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 31.91% as of today's recent price of $6.49.
EXEL: 7.34 (-0.03)
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Tue May 24, 4:15PM CDT
Exelixis, Inc. (EXEL) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).
ABT: 38.87 (-0.04), JNJ: 116.15 (-0.85), SNY: 40.16 (-0.70), EXEL: 7.34 (-0.03)
24.8% Return Seen to Date on SmarTrend Exelixis Call (EXEL)
Comtex SmarTrend(R) - Tue May 24, 1:48PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 4 weeks, Exelixis has returned 24.80% as of today's recent price of $6.14.
EXEL: 7.34 (-0.03)
Watch for Exelixis to Potentially Pullback After Gaining 7.82% Yesterday
Comtex SmarTrend(R) - Mon May 23, 2:19PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $5.70 to a high of $6.14. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $5.58 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
BusinessWire - Mon May 23, 1:31PM CDT
Regulatory News:
EXEL: 7.34 (-0.03)
Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
BusinessWire - Mon May 23, 8:03AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate- or poor-risk RCC. The safety data in the cabozantinib-treated arm of the study were consistent with those observed in previous studies in patients with advanced RCC. CABOSUN is being conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis' collaboration with the National Cancer Institute's Cancer Therapy Evaluation Program (NCI-CTEP). The final results from CABOSUN will be submitted for presentation at a future medical conference.
EXEL: 7.34 (-0.03)
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.28 (-0.01), OGXI: 1.01 (-0.09), AMGN: 156.78 (-1.22), LLY: 74.20 (-0.23), BMY: 72.18 (-0.55), MNTA: 11.80 (-0.32), CELG: 105.29 (-0.84), EXEL: 7.34 (-0.03)
After Yesterday's Rally of 7.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 13, 2:38PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $5.21 to a high of $5.57. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $5.26 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10
BusinessWire - Thu May 05, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Bank of America Merrill Lynch 2016 Health Care Conference taking place May 10-12 in Las Vegas, NV. The Exelixis presentation is scheduled for 8:00 AM PDT/11:00 AM EDT on Tuesday, May 10, 2016.
EXEL: 7.34 (-0.03)
Exelixis Shares Up 45.1% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Wed Jun 08, 12:57PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 45.12% as of today's recent price of $7.14.
EXEL: 7.34 (-0.03)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 38.87 (-0.04), JNJ: 116.15 (-0.85), PFE: 35.10 (-0.21), EXEL: 7.34 (-0.03)
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 53.69 (-2.11), EXEL: 7.34 (-0.03)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 35.10 (-0.21), BMY: 72.18 (-0.55), EXEL: 7.34 (-0.03)
SmarTrend Watching for Potential Pullback in Shares of Exelixis After 8.35% Gain
Comtex SmarTrend(R) - Mon Jun 06, 2:44PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.76 to a high of $7.34. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.80 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 7.34 (-0.03)
Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX(TM) (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO
BusinessWire - Sun Jun 05, 6:53AM CDT
--- Overall survival and progression-free survival benefits consistent across all subgroups evaluated -
EXEL: 7.34 (-0.03)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 7.34 (-0.03)
Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
BusinessWire - Sun Jun 05, 6:30AM CDT
--- Phase 3 pivotal trial of combination has been initiated -
EXEL: 7.34 (-0.03)
Exelixis Rises 4.27% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 3:16PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.46 to a high of $6.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $6.63 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Uptrend Call Working As Exelixis Stock Rises 31.9% (EXEL)
Comtex SmarTrend(R) - Wed Jun 01, 12:52AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 31.91% as of today's recent price of $6.49.
EXEL: 7.34 (-0.03)
Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
Zacks Equity Research - Zacks Investment Research - Tue May 24, 4:15PM CDT
Exelixis, Inc. (EXEL) announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC).
ABT: 38.87 (-0.04), JNJ: 116.15 (-0.85), SNY: 40.16 (-0.70), EXEL: 7.34 (-0.03)
24.8% Return Seen to Date on SmarTrend Exelixis Call (EXEL)
Comtex SmarTrend(R) - Tue May 24, 1:48PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 4 weeks, Exelixis has returned 24.80% as of today's recent price of $6.14.
EXEL: 7.34 (-0.03)
Watch for Exelixis to Potentially Pullback After Gaining 7.82% Yesterday
Comtex SmarTrend(R) - Mon May 23, 2:19PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $5.70 to a high of $6.14. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $5.58 on volume of 6.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
BusinessWire - Mon May 23, 1:31PM CDT
Regulatory News:
EXEL: 7.34 (-0.03)
Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
BusinessWire - Mon May 23, 8:03AM CDT
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate- or poor-risk RCC. The safety data in the cabozantinib-treated arm of the study were consistent with those observed in previous studies in patients with advanced RCC. CABOSUN is being conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis' collaboration with the National Cancer Institute's Cancer Therapy Evaluation Program (NCI-CTEP). The final results from CABOSUN will be submitted for presentation at a future medical conference.
EXEL: 7.34 (-0.03)
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.28 (-0.01), OGXI: 1.01 (-0.09), AMGN: 156.78 (-1.22), LLY: 74.20 (-0.23), BMY: 72.18 (-0.55), MNTA: 11.80 (-0.32), CELG: 105.29 (-0.84), EXEL: 7.34 (-0.03)
After Yesterday's Rally of 7.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri May 13, 2:38PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $5.21 to a high of $5.57. Yesterday, the shares gained 7.3%, which took the trading range above the 3-day high of $5.26 on volume of 4.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 7.34 (-0.03)
Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10
BusinessWire - Thu May 05, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Bank of America Merrill Lynch 2016 Health Care Conference taking place May 10-12 in Las Vegas, NV. The Exelixis presentation is scheduled for 8:00 AM PDT/11:00 AM EDT on Tuesday, May 10, 2016.
EXEL: 7.34 (-0.03)
